Skip to main content
Premium Trial:

Request an Annual Quote

CombiChem Achieves Milestones, Holds IPO


SAN DIEGO, Calif.--After its initial public offering earlier this month, CombiChem announced the achievement of milestones in two of its collaborations. The computational chemistry company here offered 2.25 million shares at $8 per share in the offering managed by BancAmerica Robertson Stephens, Donaldson, Lufkin & Jenrette, and Salomon Smith Barney. CombiChem offered underwriters an option to buy an additional 337,500 shares of common stock to cover over-allotments.

The company later announced that it has achieved milestones in separate drug discovery collaborations with the Japanese company Teijin and Roche Biosciences. Its Roche milestone--the result of a project begun in October 1996--related to optimization of novel inhibitors for a potential new treatment for chronic inflammatory diseases. For Teijin, CombiChem had success in the evolution and optimization of a series of novel receptor antagonists useful in various inflammatory diseases. Several compounds have been identified in the collaboration and they are now being evaluated in more detailed studies by Teijin prior to selection of a development candidate.

Filed under

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.